Paul Tardi
- Molecular Biology top 5%
- Biomaterials top 0.5%
- Biomedical Engineering top 5%
- Oncology top 5%
- Hematology top 2%
- Co-authors
- Lawrence D. MayerMarcel B. BallyTroy O. HarasymSharon A. JohnstoneNatashia HarasymDavid BermudesDawn WaterhouseNancy L. Boman
- Topics
- Nanoparticle-Based Drug Delivery (32 papers)Acute Myeloid Leukemia Research (8 papers)Cancer therapeutics and mechanisms (8 papers)
- Journals
- SHILAP Revista de lepidopterologíaBloodCancer Research
- Partner nations
- CanadaUnited StatesSweden
In The Last Decade
Paul Tardi
51 papers receiving 2.3k citations
Peers
Comparison fields: 5 of 96
- Molecular Biology 1.4k
- Biomaterials 1.2k
- Biomedical Engineering 603
- Oncology 474
- Hematology 359
Countries citing papers authored by Paul Tardi
This map shows the geographic impact of Paul Tardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Tardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Tardi more than expected).
Fields of papers citing papers by Paul Tardi
This network shows the impact of papers produced by Paul Tardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Tardi. The network helps show where Paul Tardi may publish in the future.
Co-authorship network of co-authors of Paul Tardi
This figure shows the co-authorship network connecting the top 25 collaborators of Paul Tardi. A scholar is included among the top collaborators of Paul Tardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Tardi. Paul Tardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties | 2 |
| 2 | 22 | |
| 3 | 8 | |
| 4 | 118 | |
| 5 | 61 | |
| 6 | 98 | |
| 7 | Development of highly efficacious hydrophobic paclitaxel prodrugs delivered in nanoparticles for fixed-ratio drug combination applications | 3 |
| 8 | 15 | |
| 9 | 288 | |
| 10 | 35 | |
| 11 | 29 | |
| 12 | 110 | |
| 13 | Synergistic antitumor activity observed for a fixed ratio liposome formulation of Cytarabine (Cyt):Daunorubicin (Daun) against preclinical leukemia models | 3 |
| 14 | A pharmaceutical approach to achieve synergy in vivo: A fixed ratio formulation of Irinotecan and Floxuridine for treatment of colorectal cancer | 2 |
| 15 | A novel approach to prepare a liposomal irinotecan formulations that exhibit significant therapeutic activity in vivo | 1 |
| 16 | 63 | |
| 17 | 14 | |
| 18 | 5 | |
| 19 | 10 | |
| 20 | 7 |
About Paul Tardi
Paul Tardi is a scholar working on Biomaterials, Hematology and Pharmaceutical Science, having authored 52 papers that have together received 2.5k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (32 papers), Acute Myeloid Leukemia Research (8 papers) and Cancer therapeutics and mechanisms (8 papers). The work is most often cited by research in Biomaterials (1.2k citations), Hematology (359 citations) and Pharmaceutical Science (152 citations). Paul Tardi has collaborated with scholars based in Canada, United States and Sweden. Frequent co-authors include Lawrence D. Mayer, Marcel B. Bally, Troy O. Harasym, Sharon A. Johnstone, Natashia Harasym, David Bermudes, Dawn Waterhouse, Nancy L. Boman, Natalia Zisman and Sherwin Xie. Their work appears in journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.